Drugs / REGN22044
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07526116 | May 2026 → May 2027 expected | — | Regeneron Pharmaceuticals | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | REGN22044 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07526116 ↗ |
| Route | Intravenous | “Intravenously or Subcutaneously Administered REGN22044” NCT07526116 ↗ |
| Route | Subcutaneous | “Intravenously or Subcutaneously Administered REGN22044” NCT07526116 ↗ |